Cited 0 times in
The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김상운 | - |
dc.contributor.author | 김성훈 | - |
dc.contributor.author | 김영태 | - |
dc.contributor.author | 남은지 | - |
dc.contributor.author | 이용재 | - |
dc.contributor.author | 이정윤 | - |
dc.date.accessioned | 2024-06-14T03:02:03Z | - |
dc.date.available | 2024-06-14T03:02:03Z | - |
dc.date.issued | 2024-04 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/199774 | - |
dc.description.abstract | Objective: To investigate the efficacy of cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) in predicting survival outcomes based on breast cancer gene (BRCA) mutational status in epithelial ovarian cancer. Methods: Medical records of 448 patients diagnosed with epithelial ovarian cancer at a single tertiary institution in Korea were retrospectively analyzed. Area under the curve, sensitivity, specificity, and accuracy were assessed using the CA125 and HE4 values after surgery and 3 cycles of chemotherapy to predict 1-year survival based on the BRCA mutational status. Kaplan-Meier analysis was used to obtain progression-free and overall survival to evaluate CA125 and HE4 effectiveness in predicting survival outcomes. Results: A total of 423 patients were analyzed, including 180 (42.6%) who underwent interval debulking surgery (IDS) and 243 (57.4%) who underwent primary debulking surgery (PDS). BRCA mutations were observed in 37 (15.2%) and 44 (22.4%) patients in the PDS and IDS groups, respectively. CA125 and HE4 normalization demonstrated the highest specificity in patients with or without BRCA mutations, with specificities of 97.1% and 99.1% in the PDS group and 78.6% and 86.2% in the IDS group, respectively. Normalizing HE4 alone may be an effective prognostic marker, with an area under the curve of 0.774 and specificity of 75.0%, in patients with BRCA mutations. Conclusion: Normalizing both biomarkers emerged as the most effective predictive marker for the 1-year recurrence rate, regardless of BRCA mutational status. A negative HE4 value can be a useful predictor for 1-year recurrence-free survival in patients with BRCA mutations. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Asian Society of Gynecologic Oncology : Taehan Puin Chongyang Hakhoe | - |
dc.relation.isPartOf | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics and Gynecology (산부인과학교실) | - |
dc.contributor.googleauthor | Young Joo Lee | - |
dc.contributor.googleauthor | Woojin Kim | - |
dc.contributor.googleauthor | Soomin Hong | - |
dc.contributor.googleauthor | Yong Jae Lee | - |
dc.contributor.googleauthor | Jung-Yun Lee | - |
dc.contributor.googleauthor | Sang Wun Kim | - |
dc.contributor.googleauthor | Sunghoon Kim | - |
dc.contributor.googleauthor | Young Tae Kim | - |
dc.contributor.googleauthor | Eun Ji Nam | - |
dc.identifier.doi | 10.3802/jgo.2024.35.e80 | - |
dc.contributor.localId | A00526 | - |
dc.contributor.localId | A00595 | - |
dc.contributor.localId | A00729 | - |
dc.contributor.localId | A01262 | - |
dc.contributor.localId | A05165 | - |
dc.contributor.localId | A04638 | - |
dc.relation.journalcode | J01428 | - |
dc.identifier.eissn | 2005-0399 | - |
dc.identifier.pmid | 38670560 | - |
dc.subject.keyword | BRCA1 Protein | - |
dc.subject.keyword | BRCA2 Protein | - |
dc.subject.keyword | Biomarkers, Tumor | - |
dc.subject.keyword | CA-125 Antigen | - |
dc.subject.keyword | Carcinoma, Ovarian Epithelial | - |
dc.contributor.alternativeName | Kim, Sang Wun | - |
dc.contributor.affiliatedAuthor | 김상운 | - |
dc.contributor.affiliatedAuthor | 김성훈 | - |
dc.contributor.affiliatedAuthor | 김영태 | - |
dc.contributor.affiliatedAuthor | 남은지 | - |
dc.contributor.affiliatedAuthor | 이용재 | - |
dc.contributor.affiliatedAuthor | 이정윤 | - |
dc.citation.volume | 35 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | e80 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, Vol.35(6) : e80, 2024-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.